Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases.
Location: United States, New Mexico, Torrance
Employees: 51-200
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | E&Inve... | eninvestme... |
Mentions in press and media 17
| Date | Title | Description |
| 12.10.2021 | Emmaus Life Sciences : Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos MedicineOctober 12, 2021 | Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc. (Kainos), granting Emmaus an e... |
| 17.08.2021 | Emmaus Life Sciences : Announces Bahrain Temporary License of EndariAugust 17, 2021 | TORRANCE California, August 17, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that on August 12, 2021, the National Health Reg... |
| 17.08.2021 | Emmaus Life Sciences Announces Bahrain Temporary License of Endari® USA - English USA - English | |
| 15.07.2021 | Emmaus Life Sciences : Announces Submission of Endari Marketing Authorization Application in KuwaitJuly 15, 2021 | TORRANCE California, July 15, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Au... |
| 15.06.2021 | EMMAUS LIFE SCIENCES, INC. Emmaus Life Sciences : Announces Submission of Marketing Authorization Application to SwissmedicJune 15, 2021 | Torrance CA, June 15, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency for The... |
| 15.06.2021 | Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program | |
| 26.05.2021 | EMMAUS LIFE SCIENCES, INC. Emmaus Life Sciences : Announces Submission of Marketing Authorization Application for Endari to the Saudi Food and Drug AuthorityMay 26, 2021 | TORRANCE California, May 26, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its application for Marketing Authorization (M... |
| 26.05.2021 | Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority USA - English USA - English | |
| 04.05.2021 | EMMAUS LIFE SCIENCES, INC. Emmaus Life Sciences : Reports Annual Financial Results for 2020 and Provides Updated Business ReviewMay 04, 2021 | -- Net Revenues Increased Despite COVID-19 Pandemic-Related Challenges -- -- Improved Overall Operating Results and Net Income vs. Net Loss in 2019 -- Torrance CA, May 4, 2021- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biop... |
| 04.05.2021 | Emmaus Life Sciences : Reports Annual Financial Results for 2020 and Provides Updated Business ReviewMay 04, 2021 | -- Net Revenues Increased Despite COVID-19 Pandemic-Related Challenges -- -- Improved Overall Operating Results and Net Income vs. Net Loss in 2019 -- Torrance CA, May 4, 2021- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biop... |
Show more